These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12917315)

  • 1. Pneumococcal vaccination in older adults.
    Hirschmann JV
    N Engl J Med; 2003 Aug; 349(7):712-4; author reply 712-4. PubMed ID: 12917315
    [No Abstract]   [Full Text] [Related]  

  • 2. Pneumococcal vaccination in older adults.
    Marras TK
    N Engl J Med; 2003 Aug; 349(7):712-4; author reply 712-4. PubMed ID: 12924340
    [No Abstract]   [Full Text] [Related]  

  • 3. Pneumococcal vaccination in older adults.
    Fedson DS
    N Engl J Med; 2003 Aug; 349(7):712-4; author reply 712-4. PubMed ID: 12924341
    [No Abstract]   [Full Text] [Related]  

  • 4. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA; Berg S; Hemlin C; Jokinen I
    Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
    Ortqvist A; Jönsson B; Baltussen R; Ament A
    Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pneumococcal vaccine for the elderly--ineffective but cost-efficient?].
    Håkansson J
    Lakartidningen; 2000 Dec; 97(50):5958. PubMed ID: 11188544
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
    Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
    Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The elderly should be vaccinated against pneumococci].
    Ortqvist A; Hedlund J; Kalin M
    Lakartidningen; 1999 Mar; 96(11):1305-8. PubMed ID: 10194909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pneumococcal infections. Every second fatality within 48 hours].
    MMW Fortschr Med; 2001 Nov; 143(47):60. PubMed ID: 11791369
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
    Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A vaccination would prevent invasive pneumococcal infections in adults].
    Herva E; Sankilampi U; Leinonen M
    Duodecim; 1997; 113(8):689-91. PubMed ID: 11466867
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
    Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
    Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
    Lucioni C; Mazzi S
    Vaccine; 2006 Mar; 24(11):1735. PubMed ID: 16356601
    [No Abstract]   [Full Text] [Related]  

  • 19. Pneumococcal vaccination: yes or no.
    Sharda KB
    Indian Pediatr; 2008 Jun; 45(6):519. PubMed ID: 18599950
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey.
    Akin L; Kaya M; Altinel S; Durand L
    Hum Vaccin; 2011 Apr; 7(4):441-50. PubMed ID: 21441776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.